USA - NYSEARCA:AMS - US0295951059 - Common Stock
The current stock price of AMS is 2.06 USD. In the past month the price decreased by -11.97%. In the past year, price decreased by -32.35%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.32 | 98.35B | ||
| CI | THE CIGNA GROUP | 9.09 | 68.91B | ||
| LH | LABCORP HOLDINGS INC | 16.51 | 21.70B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.88 | 20.61B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 111.76 | 20.20B | ||
| GH | GUARDANT HEALTH INC | N/A | 12.21B | ||
| HIMS | HIMS & HERS HEALTH INC | 76.02 | 9.28B | ||
| DVA | DAVITA INC | 13.02 | 8.59B | ||
| CHE | CHEMED CORP | 19.82 | 6.35B | ||
| RDNT | RADNET INC | 212.76 | 6.22B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 32.91 | 5.95B | ||
| OPCH | OPTION CARE HEALTH INC | 18.92 | 4.57B |
American Shared Hospital Services engages in leasing radiosurgery and radiation therapy equipment to healthcare providers. The company is headquartered in San Francisco, California and currently employs 81 full-time employees. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). The company can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The firm provides radiation therapy services both domestically and internationally.
AMERICAN SHARED HOSPITAL SER
601 Montgomery Street, Suite 1112
San Francisco CALIFORNIA 94111 US
CEO: Raymond C. Stachowiak
Employees: 82
Phone: 14157885300
American Shared Hospital Services engages in leasing radiosurgery and radiation therapy equipment to healthcare providers. The company is headquartered in San Francisco, California and currently employs 81 full-time employees. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). The company can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The firm provides radiation therapy services both domestically and internationally.
The current stock price of AMS is 2.06 USD.
AMS does not pay a dividend.
AMS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
AMS stock is listed on the NYSE Arca exchange.
AMERICAN SHARED HOSPITAL SER (AMS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
AMERICAN SHARED HOSPITAL SER (AMS) currently has 82 employees.
ChartMill assigns a fundamental rating of 2 / 10 to AMS. AMS may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months AMS reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -511.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.84% | ||
| ROE | -9.97% | ||
| Debt/Equity | 0.58 |
5 analysts have analysed AMS and the average price target is 4.59 USD. This implies a price increase of 122.82% is expected in the next year compared to the current price of 2.06.
For the next year, analysts expect an EPS growth of 49.5% and a revenue growth 9.31% for AMS